Anti-ENTP8/ ENTPD8/ E-NTPDase monoclonal antibody

Anti-ENTP8/ ENTPD8/ E-NTPDase antibody for FACS & in-vivo assay

Target products collectionGo to ENTPD8/ENTPD8 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)

pdfMSDSpdfCOApdfDatasheet

Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-MP0417-Ab-1/ GM-Tg-hg-MP0417-Ab-2Anti-Human ENTPD8 monoclonal antibodyHuman
GM-Tg-rg-MP0417-Ab-1/ GM-Tg-rg-MP0417-Ab-2Anti-Rat ENTPD8 monoclonal antibodyRat
GM-Tg-mg-MP0417-Ab-1/ GM-Tg-mg-MP0417-Ab-2Anti-Mouse ENTPD8 monoclonal antibodyMouse
GM-Tg-cynog-MP0417-Ab-1/ GM-Tg-cynog-MP0417-Ab-2Anti-Cynomolgus/ Rhesus macaque ENTPD8 monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-MP0417-Ab-1/ GM-Tg-felg-MP0417-Ab-2Anti-Feline ENTPD8 monoclonal antibodyFeline
GM-Tg-cang-MP0417-Ab-1/ GM-Tg-cang-MP0417-Ab-2Anti-Canine ENTPD8 monoclonal antibodyCanine
GM-Tg-bovg-MP0417-Ab-1/ GM-Tg-bovg-MP0417-Ab-2Anti-Bovine ENTPD8 monoclonal antibodyBovine
GM-Tg-equg-MP0417-Ab-1/ GM-Tg-equg-MP0417-Ab-2Anti-Equine ENTPD8 monoclonal antibodyEquine

Size： 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-MP0417-Ab-1/ GM-Tg-hg-MP0417-Ab-2; GM-Tg-rg-MP0417-Ab-1/ GM-Tg-rg-MP0417-Ab-2;
GM-Tg-mg-MP0417-Ab-1/ GM-Tg-mg-MP0417-Ab-2; GM-Tg-cynog-MP0417-Ab-1/ GM-Tg-cynog-MP0417-Ab-2;
GM-Tg-felg-MP0417-Ab-1/ GM-Tg-felg-MP0417-Ab-2; GM-Tg-cang-MP0417-Ab-1/ GM-Tg-cang-MP0417-Ab-2;
GM-Tg-bovg-MP0417-Ab-1/ GM-Tg-bovg-MP0417-Ab-2; GM-Tg-equg-MP0417-Ab-1/ GM-Tg-equg-MP0417-Ab-2
Products NameAnti-ENTPD8 monoclonal antibody
Formatmab
Target NameENTPD8
Protein Sub-locationTransmembrane Protein
Category of antibodyFACS/Biofunctional Antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)		IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by using flow cytometry with antigen overexpressed cell line. The biofunction of antibodies are validated in cell-based assay (IC50 or EC50 TBD).
TagFc
Products descriptionPre-made anti-ENTPD8 benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS,ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    Target AntigenProducts DevelopingMulti-species ENTP8/ ENTPD8/ E-NTPDase VLP (virus-like particle) (Products Developing)


    Target information

    Target IDGM-MP0417
    Target NameENTPD8
    Gene ID377841,72090,613267,704424,100688937,101085582,515532,100058558
    Gene Symbol and SynonymsE-NTPDase,ENTPD8,GLSR2492,NTPDase-8,UNQ2492
    Uniprot AccessionQ5MY95,Q5DRK1,A0JND9
    Uniprot Entry NameENTP8_HUMAN,ENTP8_RAT,ENTP8_BOVIN
    Protein Sub-locationTransmembrane Protein
    Category
    DiseaseN/A
    Gene EnsemblENSG00000188833
    Target ClassificationN/A

    The target: ENTPD8, gene name: ENTPD8, also named as E-NTPDase, GLSR2492, NTPDase-8, UNQ2492. Predicted to enable guanosine-diphosphatase activity and uridine-diphosphatase activity. Predicted to be involved in nucleoside diphosphate catabolic process. Predicted to act upstream of or within nucleoside diphosphate biosynthetic process and nucleoside monophosphate biosynthetic process. Predicted to be integral component of membrane. Predicted to be active in plasma membrane. [provided by Alliance of Genome Resources, Apr 2022].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.